Results 11 to 20 of about 71,732 (247)

Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group

Blood Cancer Journal, 2022
Effective systemic therapies suppress toxic light chain production leading to an increased proportion of patients with light chain (AL) amyloidosis who survive longer albeit with end-stage renal disease.
Andrea Havasi, Cihan Heybeli, Nelson Leung, Avital Angel-Korman, Vaishali Sanchorawala, Oliver Cohen, Ashutosh Wechalekar, Frank Bridoux, Insara Jaffer, Victoria Gutgarts, Hani Hassoun, Maya Levinson, Cara Rosenbaum, Paolo Milani, Giovanni Palladini, Giampaolo Merlini, Ute Hegenbart, Stefan Schönland, Kaya Veelken, Alexander Pogrebinsky, Gheorghe Doros, Heather Landau   +21 more
doaj   +1 more source

Amyloidosis [PDF]

Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2012
The term amyloid describes the deposition in the extracellular space of certain proteins in a highly characteristic, insoluble fibrillar form. Amyloidosis describes the various clinical syndromes that occur as a result of damage by amyloid deposits in tissues and organs throughout the body.
Jennifer H, Pinney, Philip N, Hawkins
openaire   +2 more sources

Systemic amyloid light‐chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates [PDF]

Ca-A Cancer Journal for Clinicians
Yihan Cao, Heather Landau, Raymond Comenzo   +2 more
exaly   +2 more sources

Navigating the Complex Web of Prescribing Amyloidosis Therapeutics: A Primer

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Advancement in the diagnosis and treatment of transthyretin amyloid cardiomyopathy has made great strides in recent years. Novel therapeutics for transthyretin amyloidosis such as tafamidis, patisiran, and inotersen have shown significant benefits in a ...
Hongya Chen, Pranav Chandrashekar, Katherine Fischer, Dayna Carlson, Urja Narayan, Jack Chen, Ahmad Masri   +6 more
doaj   +1 more source

Clinical Amyloid Typing by Proteomics: Performance Evaluation and Data Sharing between Two Centres

Molecules, 2021
Amyloidosis is a relatively rare human disease caused by the deposition of abnormal protein fibres in the extracellular space of various tissues, impairing their normal function. Proteomic analysis of patients’ biopsies, developed by Dogan and colleagues
Diana Canetti, Francesca Brambilla, Nigel B. Rendell, Paola Nocerino, Janet A. Gilbertson, Dario Di Silvestre, Andrea Bergamaschi, Francesca Lavatelli, Giampaolo Merlini, Julian D. Gillmore, Vittorio Bellotti, Pierluigi Mauri, Graham W. Taylor   +12 more
doaj   +1 more source

Proteomic Analysis for the Diagnosis of Fibrinogen Aα-chain Amyloidosis

Kidney International Reports, 2019
Introduction: Hereditary fibrinogen Aα-chain (AFib) amyloidosis is a relatively uncommon renal disease associated with a small number of pathogenic fibrinogen Aα (FibA) variants; wild-type FibA normally does not result in amyloid deposition.
Graham W. Taylor, Janet A. Gilbertson, Rabya Sayed, Angel Blanco, Nigel B. Rendell, Dorota Rowczenio, Tamer Rezk, P. Patrizia Mangione, Diana Canetti, Paul Bass, Philip N. Hawkins, Julian D. Gillmore   +11 more
doaj   +1 more source

A nationwide assessment of hepatocellular adenoma resection: Indications and pathological discordance

Hepatology Communications, EarlyView., 2022
Abstract Hepatocellular adenomas (HCAs) are benign liver tumors associated with bleeding or malignant transformation. Data on the indication for surgery are scarce. We analyzed indications and outcome of patients operated for HCAs < 50 mm compared to HCAs ≥ 50 mm. Changes in final postoperative diagnosis were assessed.
Martijn P. D. Haring, Arthur K. E. Elfrink, Christiaan A. J. Oudmaijer, Paul C. M. Andel, Alicia Furumaya, Nenke de Jong, Colin J. J. M. Willems, Thijs Huits, Julie M. L. Sijmons, Eric J. T. Belt, Koop Bosscha, Esther C. J. Consten, Mariëlle M. E. Coolsen, Peter van Duijvendijk, Joris I. Erdmann, Paul Gobardhan, Robbert J. de Haas, Tjarda van Heek, Hwai‐Ding Lam, Wouter K. G. Leclercq, Mike S. L. Liem, Hendrik A. Marsman, Gijs A. Patijn, Türkan Terkivatan, Babs M. Zonderhuis, Izaak Quintus Molenaar, Wouter W. te Riele, Jeroen Hagendoorn, Alexander F. M. Schaapherder, Jan N. M. IJzermans, Carlijn I. Buis, Joost M. Klaase, Koert P. de Jong, Vincent E. de Meijer, the Dutch Benign Liver Tumor Group, R. B. Takkenberg, J. Verheij, O. M. van Delden, J. I. Erdmann, B. V. van Rosmalen, A. Furumaya, G. Kazemier, D. Ramsoekh, J. N. M. IJzermans, R. A. de Man, M. D. Doukas, M. G. Thomeer, A. J. Klompenhouwer, A. F. M. Schaapherder, M. E. Tushuizen, M. J. Coenraad, A. S. L. P. Crobach, M. C. Burgmans, S. Feshtali, M. M. E. Coolsen, M. Kramer, J. C. Beckervordersandforth, I. V. Samarska, C. van der Leij, R. Miclea, J. H. W. de Wilt, P. B. van den Boezem, E. T. T. L. Tjwa, I. Munsterman, S. Vos, S. van Koeverden, V. E. de Meijer, F. J. C. Cuperus, R. J. de Haas, E. W. Duiker, M. P. D. Haring   +70 more
wiley   +1 more source

Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study

Blood Cancer Journal, 2021
The recent decades have ushered in considerable advancements in the diagnosis and treatment of systemic light chain (AL) amyloidosis. As disease outcomes improve, AL amyloidosis-unrelated factors may impact mortality. In this study, we evaluated survival
Andrew Staron, Luke Zheng, Gheorghe Doros, Lawreen H. Connors, Lisa M. Mendelson, Tracy Joshi, Vaishali Sanchorawala   +6 more
doaj   +1 more source

Amyloidosis

Blood Reviews, 1988
Amyloidosis is a disorder of protein folding in which normally soluble proteins are deposited in the interstitial space as insoluble and remarkably stable fibrils that progressively disrupt tissue structure and function of organs throughout the body.
openaire   +5 more sources

Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein

Kidney International Reports, 2017
Fibrinogen A alpha chain amyloidosis is an autosomal dominant disease associated with mutations in the fibrinogen A alpha chain (FGA) gene, and it is the most common cause of hereditary renal amyloidosis in the UK.
Dorota Rowczenio, Maria Stensland, Gustavo A. de Souza, Erik H. Strøm, Janet A. Gilbertson, Graham Taylor, Nigel Rendell, Shane Minogue, Yvonne A. Efebera, Helen J. Lachmann, Ashutosh D. Wechalekar, Philip N. Hawkins, Ketil R. Heimdal, Kristian Selvig, Inger K. Lægreid, Nathalie Demoulin, Selda Aydin, Julian D. Gillmore, Tale N. Wien   +18 more
doaj   +1 more source